PPA
JANX icon

Parametric Portfolio Associates’s Janux Therapeutics JANX Stock Holding History

Parametric Portfolio Associates’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-59,366
Closed -$1.28M – 3670
2021
Q3 		$1.28M Buy
+59,366
New +$1.71M ﹤0.01% 2684

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Parametric Portfolio Associates's JANX Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Janux Therapeutics (JANX) in Q4 2021, closing a stake of 59,366 shares — an estimated $1.28M sold.

Parametric Portfolio Associates first reported a position in JANX in Q3 2021 and held it in 1 quarter. The position peaked at $1.28M in Q3 2021. 46 funds tracked by Wall St. Rank hold JANX as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Janux Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 59,366 Janux Therapeutics shares in Q4 2021, an estimated $1.28M.
  • Parametric Portfolio Associates first reported a position in Janux Therapeutics in Q3 2021 and held it in 1 quarter.
  • Parametric Portfolio Associates's Janux Therapeutics position peaked at $1.28M in Q3 2021.
  • 46 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.